All Updates

All Updates

icon
Filter
Funding
NewLimit raises USD 40 million in Series A funding
Precision Medicine
May 16, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Funding
Apaleo raises EUR 20 million in growth equity funding to accelerate expansion
Travel Tech
Yesterday
Partnerships
Acai Travel partners with Hopper to enhance call center operations with AI technology
Travel Tech
Yesterday
Product updates
BrightEdge releases AI capabilities to monitor and analyze brand presence in Google AI Overview search results
Marketing Automation
Yesterday
Precision Medicine

Precision Medicine

May 16, 2023

NewLimit raises USD 40 million in Series A funding

Funding

  • Anti-aging biotech company NewLimit has raised USD 40 million in a Series A funding round led by Dimension, Founders Fund, and Kleiner Perkins. Investors such as Eric Schmidt, Elad Gil, Garry Tan, and Fred Ehrsam also participated. The latest funding adds to the initial USD 110 million from the founders. 

  • The funds will be used to support its workforce. 

  • NewLimit is a biotechnology company focused on treatments that target aging by identifying transcription factors that can epigenetically reprogram cells using machine learning. With a focus on T cells, they aim to rejuvenate the immune systems of older individuals and develop products that target aging and associated diseases, such as fibrosis, infectious disease, and neurodegenerative disease. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.